mTOR inhibitor Everolimus-induced apoptosis in melanoma cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Melanoma is an aggressive skin cancer resistant to therapy.
• Mammalian target of rapamycin (mTOR) signaling is crucial for cell growth and survival.
• mTOR pathway dysregulation contributes to melanoma progression.

Purpose of the Study:

• To compare the effects of everolimus (mTOR inhibitor) alone and in combination with downstream kinase inhibitors on melanoma cells.
• To evaluate the impact on pro-survival proteins, caspase-3 activity, proliferation, and apoptosis.

Main Methods:

• Melanoma cells were treated with varying concentrations of everolimus (20 nM to 10 μM).
• Combinations included inhibitors of PI3K (LY294002), ERK1/2 (U0126), MEK (AS-703026), and AKT (MK-2206).
• Assessed were protein expression (p-Bcl-2, Bcl-2, Bcl-xL, Mcl-1), caspase-3 activity, proliferation, and apoptosis.

Main Results:

• Nanomolar concentrations of everolimus combined with AS-703026 (MEK inhibitor) or MK-2206 (AKT inhibitor) significantly induced apoptosis.
• These combinations effectively reduced melanoma cell proliferation.
• The study observed modulation of pro-survival protein expression and caspase-3 activity.

Conclusions:

• mTOR signaling plays a vital role in melanoma progression.
• Combination therapy using nanomolar everolimus with specific downstream inhibitors (AS-703026 or MK-2206) is effective against melanoma.
• These findings support the potential clinical application of combined mTOR and downstream kinase inhibition for melanoma treatment.